Executive Summary
According to Azoth Analytics research report, the Global Rare Disease Drugs was valued at USD 147.12 Billion in the year 2021. The increasing focus on research activities and the development of novel therapeutic drugs has facilitated the growth of the Rare Disease Drugs market. Additionally, growing product developments is leading to the implementation of technologically driven innovative devices in the diagnosis of rare genetic disorders.
Moreover, favourable government policies aiming at creating awareness pertaining to the Rare Disease treatment are leading to increased adoption of effective treatments of rare disorders. However, there are several factors hindering the efficient and effective clinical trials of drug development of rare disorders including low patient numbers, limited understanding of pathology and progression, and lack of established endpoints. Therefore, several regulatory bodies are engaged in implementing regulatory standards for drug approval for Rare diseases to ensure patient safety and efficacy of drugs.
Furthermore, improved detection and increased rates of diagnosis of Rare diseases are likely to contribute to rising costs. While the humanitarian benefits of Rare Disease therapies are indisputable, concerns regarding high treatment costs play a meaningful role in how payers administer and manage healthcare benefits that ultimately dictate patient access to orphan drugs. Moreover, the biological drugs are used for treating Rare diseases such as cancer with fewer side effects that have a high prevalence rate in the developed world.
Scope of the Report
- The report presents the analysis of the Rare Disease Drugs market for the historical period of 2017-2021 and the forecast period of 2022-2027.
- The report analyses the Rare Disease Drugs Market by Value (USD Billion).
- The report analyses the Rare Disease Drugs Market by Drug Type (Biologics, Non-Biologics).
- The report analyses the Rare Disease Drugs Market by Therapeutic Area (Infectious Disease, Oncology, Neurology, Metabolic, Others).
- The report analyses the Rare Disease Drugs Market by Patients (Pediatric, Adults).
- The report analyses the Rare Disease Drugs Market by Route of Administration (Oral, Injectable).
- The report analyses the Rare Disease Drugs Market by Distribution Channel (Hospital & Retail Pharmacies, Online Pharmacies).
- The Global Rare Disease Drugs Market has been analysed By Region (North America, Europe, Asia Pacific and LAMEA).
- The Global Rare Disease Drugs Market has been analysed By Country (United States, Canada, Germany, United Kingdom, France, Italy, China, Japan, India, South Korea).
- The attractiveness of the market has been presented by region, by Drug Type, by Therapeutic area, by patients, by Route of Administration and by Distribution Channel
- Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
- The companies analysed in the report include Takeda Pharmaceutical Company Limited, Sanofi, Merck KGaA, F. Hoffman-La Roche Ltd., Pfizer, Novartis AG, Bayer Group, Biogen, GlaxoSmithKline, AbbVie Inc.
Key Target Audience
- Rare Disease Drugs Manufacturers
- Healthcare and Pharmaceutical Companies
- Consulting and Advisory Firms
- Government and Policy Makers
- Regulatory Authorities
Global Rare Disease Drugs Market (2022 Edition) - Analysis By Drug Type, Therapeutic Area, Patients, Route of Administration, Distribution Channel, By Region, By Country (2022 Edition): Market Insights, and Forecast with Impact of COVID-19 (2022-2027)
Table of Contents
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Rare Disease Drugs Market: Product Outlook
4. Global Rare Disease Drugs Market: Sizing and Forecast
4.1 Global Rare Disease Drugs Market Size, By Value, 2017-2027
4.2 Impact of COVID-19 on Global Rare Disease Drugs Market
5. Global Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel
5.1 Competitive Scenario of Global Rare Disease Drugs Market: By Drug Type
5.1.1 Biologics - Market Size and Forecast (2017-2027)
5.1.2 Non-Biologics - Market Size and Forecast (2017-2027)
5.2 Competitive Scenario of Global Rare Disease Drugs Market: By Therapeutic Area
5.2.1 Infectious disease - Market Size and Forecast (2017-2027)
5.2.2 Oncology- Market Size and Forecast (2017-2027)
5.2.3 Neurological - Market Size and Forecast (2017-2027)
5.2.4 Metabolic - Market Size and Forecast (2017-2027)
5.2.5 Others - Market Size and Forecast (2017-2027)
5.3 Competitive Scenario of Global Rare Disease Drugs Market: By Patients
5.3.1 Paediatric - Market Size and Forecast (2017-2027)
5.3.2 Adults - Market Size and Forecast (2017-2027)
5.4 Competitive Scenario of Global Rare Disease Drugs Market: By Route of Administration
5.4.1 Oral - Market Size and Forecast (2017-2027)
5.4.2 Injectable - Market Size and Forecast (2017-2027)
5.5 Competitive Scenario of Global Rare Disease Drugs Market: By Distribution Channel
5.5.1 Hospitals & Retail Pharmacies- Market Size and Forecast (2017-2027)
5.5.2 Online Pharmacies - Market Size and Forecast (2017-2027)
6. Global Rare Disease Drugs Market: Regional Analysis
6.1 Competitive Scenario of Global Rare Disease Drugs Market: By Region
7. North America Rare Disease Drugs Market: An Analysis (2017-2027)
7.1 North America Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
7.2 North America Rare Disease Drugs Market - Prominent Companies
7.3 Market Segmentation By Drug Type (Biologics, Non-Biologics)
7.4 Market Segmentation By Therapeutic Area (Infectious Disease, Oncology, Neurological, Metabolic and Others)
7.5 Market Segmentation By Patients Type (Pediatric, Adults)
7.6 Market Segmentation By Route of Administration (Oral, Injectable)
7.7 Market Segmentation By Distribution Channel (Hospitals & Retail Pharmacies, Online Pharmacies)
7.8 North America Rare Disease Drugs Market: Country Analysis
7.9 Market Opportunity Chart of North America Rare Disease Drugs Market - By Country, By Value, 2027
7.10 Competitive Scenario of North America Rare Disease Drugs Market: By Country
7.11 United States Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
7.12 United States Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
7.13 Canada Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
7.14 Canada Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
8. Europe Rare Disease Drugs Market: An Analysis (2017-2027)
8.1 Europe Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.2 Europe Rare Disease Drugs Market - Prominent Companies
8.3 Market Segmentation By Drug Type (Biologics, Non-Biologics)
8.4 Market Segmentation By Therapeutic Area (Infectious Disease, Oncology, Neurological, Metabolic, Others)
8.5 Market Segmentation By Patients Type (Pediatric, Adults)
8.6 Market Segmentation By Route of Administration (Oral, Injectable)
8.7 Market Segmentation By Distribution Channel (Hospitals & Retail Pharmacies, Online Pharmacies)
8.8 Europe Rare Disease Drugs Market: Country Analysis
8.9 Market Opportunity Chart of Europe Rare Disease Drugs Market - By Country, By Value, 2027
8.10 Competitive Scenario of Europe Rare Disease Drugs Market: By Country
8.11 Germany Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.12 Germany Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
8.13 United Kingdom Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.14 United Kingdom Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
8.15 France Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.16 France Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
8.17 Italy Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
8.18 Italy Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
9. Asia Pacific Rare Disease Drugs Market: An Analysis (2017-2027)
9.1 Asia Pacific Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.2 Asia Pacific Rare Disease Drugs Market - Prominent Companies
9.3 Market Segmentation By Drug Type (Biologics, Non-Biologics)
9.4 Market Segmentation By Therapeutic Area (Infectious Disease, Oncology, Neurological, Metabolic, Others)
9.5 Market Segmentation By Patients Type (Pediatric, Adults)
9.6 Market Segmentation By Route of Administration (Oral, Injectable)
9.7 Market Segmentation By Distribution Channel (Hospitals & Retail Pharmacies, Online Pharmacies)
9.8 Asia Pacific Rare Disease Drugs Market: Country Analysis
9.9 Market Opportunity Chart of Asia Pacific Rare Disease Drugs Market - By Country, By Value, 2027
9.10 Competitive Scenario of Asia Pacific Rare Disease Drugs Market: By Country
9.11 China Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.12 China Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
9.13 Japan Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.14 Japan Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
9.15 India Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.16 India Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
9.17 South Korea Rare Disease Drugs Market: Size and Forecast (2017-2027), By Value
9.18 South Korea Rare Disease Drugs Market Segmentation - By Drug Type, By Therapeutic Area, By Patients, By Route of Administration, By Distribution Channel (2017-2027)
10. Global Rare Disease Drugs Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Drug Class, 2027
11.2 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Therapeutic Area, 2027
11.3 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Patients, 2027
11.4 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Route of Administration, 2027
11.5 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Distribution Channel, 2027
11.6 Market Attractiveness Chart of Global Rare Disease Drugs Market - By Region, 2027
12. Competitive Landscape
12.1 Market Share Analysis
13. Company Analysis
13.1 Takeda Pharmaceutical Company Limited
13.2 Sanofi
13.3 Merck KGaA
13.4 F. Hoffman-La Roche Ltd.
13.5 Pfizer
13.6 Novartis AG
13.7 Bayer Group
13.8 Biogen
13.9 GlaxoSmithKline
13.10 AbbVie Inc.
List of Figures
Figure 1: Global Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 2: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 3: Global Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 4: Global Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 5: Prevalence of Rare Disease Drugss in the U.S., EU, and estimated prevalence in China, (In Million)2021
Figure 6: World's leading causes of death (in millions), 2018
Figure 7: World Population 65 Years & Above (% of Total), 2015-2019
Figure 8: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 9: Global Rare Disease Drugs - Clinical Trial
Figure 10: Global Rare Disease Drugs Market- By Drug Type Market Share, 2021 & 2027
Figure 11: Global Rare Disease Drugs Market- By Biologics, By Value (USD Billion), 2017-2027
Figure 12: Global Rare Disease Drugs Market- By Non-Biologics, By Value (USD Billion), 2017-2027
Figure 13: Global Rare Disease Drugs Market- By Therapeutic Area Market Share, 2021 & 2027
Figure 14: Global Rare Disease Drugs Market- By Infectious Disease, By Value (USD Billion), 2017-2027
Figure 15: Global Rare Disease Drugs Market- By Oncology, By Value (USD Billion), 2017-2027
Figure 16: Global Rare Disease Drugs Market- By Neurological, By Value (USD Billion), 2017-2027
Figure 17: Global Rare Disease Drugs Market- By Metabolic, By Value (USD Billion), 2017-2027
Figure 18: Global Rare Disease Drugs Market- By Others, By Value (USD Billion), 2017-2027
Figure 19: Global Rare Disease Drugs Market- By patients Market Share, 2021 & 2027
Figure 20: Global Rare Disease Drugs Market- By Pediatric, By Value (USD Billion), 2017-2027
Figure 21: Global Rare Disease Drugs Market- By Adults, By Value (USD Billion), 2017-2027
Figure 22: Global Rare Disease Drugs Market- By Route of Administration Market Share, 2021 & 2027
Figure 23: Global Rare Disease Drugs Market- By Oral, By Value (USD Billion), 2017-2027
Figure 24: Global Rare Disease Drugs Market- By Injectable, By Value (USD Billion), 2017-2027
Figure 25: Global Rare Disease Drugs Market- By Distribution Channel Market Share, 2021 & 2027
Figure 26: Global Rare Disease Drugs Market- By Hospital & Retail Pharmacies, By Value (USD Billion), 2017-2027
Figure 27: Global Rare Disease Drugs Market- By Online Pharmacies, By Value (USD Billion), 2017-2027
Figure 28: Global Rare Disease Drugs Market- By Region Market Share, 2021 & 2027
Figure 29: North America Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 30: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 31: North America Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 32: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 33: North America Population ages 65 and above (% of total Population), 2016-2020
Figure 34: North America Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 35: North America Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 36: North America Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 37: North America Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 38: North America Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 39: North America Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 40: Market Opportunity Chart of North America Rare Disease Drugs Market- By Country, By Value (Year-2027)
Figure 41: North America Rare Disease Drugs Market- By Country Market Share, 2021 & 2027
Figure 42: United States Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 43: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 44: United State Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 45: United State Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 46: United States Population aged 65 and above (% of total Population), 2016-2020
Figure 47: United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 48: United State National Institute of Health Spending on Rare Disease Drugs, ( USD Million), 2016-2020
Figure 49: Median U.S. cost per patient per year for top 100 products, 2015-2018
Figure 50: United States Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 51: United States Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 52: United States Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 53: United States Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 54: United States Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 55: Canada Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 56: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 57: Canada Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 58: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 59: Canada Population aged 65 and above (% of total Population), 2016-2020
Figure 60: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 61: Canada Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 62: Canada Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 63: Canada Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 64: Canada Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 65: Canada Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 66: Europe Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 67: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 68: Europe Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 69: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 70: European Countries Population ages 65 and above (% of total Population), 2020
Figure 71: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 72: Europe Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 73: Europe Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 74: Europe Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 75: Europe Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 76: Europe Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 77: Market Opportunity Chart of Europe Rare Disease Drugs Market- By Country, By Value (Year -2027)
Figure 78: Europe Rare Disease Drugs Market- By Country Market Share, 2021 & 2027
Figure 79: Germany Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 80: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 81: Germany Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 82: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 83: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 84: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 85: Germany Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 86: Germany Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 87: Germany Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 88: Germany Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 89: Germany Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 90: United Kingdom Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 91: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 92: United Kingdom Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 93: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 94: United Kingdom Population ages 65 and above (% of total Population), 2016-20
Figure 95: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 96: United Kingdom Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 97: United Kingdom Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 98: United Kingdom Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 99: United Kingdom Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 100: United Kingdom Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 101: France Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 102: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 103: France Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 104: France Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 105: France Population ages 65 and above (% of total Population), 2016-20
Figure 106: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 107: France Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 108: France Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 109: France Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 110: France Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 111: France Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 112: Italy Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 113: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 114: Italy Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 115: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 116: Italy Population ages 65 and above (% of total Population), 2016-20
Figure 117: Italy Trend of expenditure for orphan drugs in Italy from 2016 to 2020 (In Euro USD)
Figure 118: Italy Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 119: Italy Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 120: Italy Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 121: Italy Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 122: Italy Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 123: Asia Pacific Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 124: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 125: Asia Pacific Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 126: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 127: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
Figure 128: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 129: Asia Pacific Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 130: Asia Pacific Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 131: Asia Pacific Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 132: Asia Pacific Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 133: Asia Pacific Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 134: Market Opportunity Chart of APAC Rare Disease Drugs Market- By Country, By Value (Year -2027)
Figure 135: APAC Rare Disease Drugs Market- By Country Market Share, 2021 & 2027
Figure 136: China Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 137: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 138: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 139: China Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 140: China Population ages 65 and above, by Countries (% of total Population), 2020
Figure 141: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 142: China Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 143: China Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 144: China Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 145: China Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 146: China Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 147: Japan Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 148: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 149: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 150: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 151: Japan Population ages 65 and above (% of total Population), 2016-20
Figure 152: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 153: Japan Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 154: Japan Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 155: Japan Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 156: Japan Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 157: Japan Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 158: India Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 159: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 160: India Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 161: India Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 162: India Population ages 65 and above (% of total Population), 2016-20
Figure 163: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 164: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 165: e-pharmacy market in India (USD Million)
Figure 166: India Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 167: India Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 168: India Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 169: India Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 170: India Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 171: South Korea Rare Disease Drugs Market Size, By Value, 2017-2027 (USD Billion)
Figure 172: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 173: South Korea Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 174: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 175: South Korea Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 176: South Korea Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 177: South Korea Rare Disease Drugs Market - By Drug Type, By Value (USD Billion), 2017-2027
Figure 178: South Korea Rare Disease Drugs Market - By Therapeutic Area, By Value (USD Billion), 2017-2027
Figure 179: South Korea Rare Disease Drugs Market - By Patients, By Value (USD Billion), 2017-2027
Figure 180: South Korea Rare Disease Drugs Market - By Route of Administration, By Value (USD Billion), 2017-2027
Figure 181: South Korea Rare Disease Drugs Market - By Distribution Channel, By Value (USD Billion), 2017-2027
Figure 182: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Drug Type (Year -2027)
Figure 183: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Therapeutic Area (Year-2027)
Figure 184: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Patients(Year -2027)
Figure 185: Market Attractiveness Chart of Global Rare Disease Drugs Market- By route of Administration (Year -2027)
Figure 186: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Distribution Channel (Year-2027)
Figure 187: Market Attractiveness Chart of Global Rare Disease Drugs Market- By Region (Year -2027)
Figure 188: Global Rare Disease Drugs company market share (%), 2020
Figure 189: Takeda Pharmaceutical Company Limited Sales Revenues, 2016-2020 (USD Million)
Figure 190: Takeda Pharmaceutical Company Limited Net Income, 2016-2020 (USD Million)
Figure 191: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Business Segment (%), FY2020
Figure 192: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Geography Segment (%), FY2020
Figure 193: Sanofi Sales Revenues, 2016-2020 (USD Million)
Figure 194: Sanofi Gross Profit, 2016-2020 (USD Million)
Figure 195: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Figure 196: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
Figure 197: Merck KGaA Sales Revenues, 2016-2020 (USD Million)
Figure 198: Merck KGaA Gross Profit, 2016-2020 (USD Million)
Figure 199: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020
Figure 200: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020
Figure 201: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 202: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
Figure 203: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
Figure 204: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 205: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Figure 206: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Figure 207: Pfizer sales Revenue, By Geographical Segment (%), FY2020
Figure 208: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 209: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 200: Novartis Sales Revenue Split, By Business Segment (USD Billion), FY2020
Figure 211: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 212: Bayer Group Sales Revenues, 2016-2020 (USD Million)
Figure 213: Bayer Group Net Profit, 2016-2020 (USD Million)
Figure 214: Bayer Group, By Business Segment (%), FY2020
Figure 215: Bayer Group, By Geographical Segment (%), FY2020
Figure 216: Biogen Sales Revenues, 2016-2020 (USD Million)
Figure 217: Biogen Net Profit, 2016-2020 (USD Million)
Figure 218: Biogen, By Business Segment (%), FY2020
Figure 219: Biogen, By Geographical Segment (%), FY2020
Figure 220: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 221: GlaxoSmithKline Gross Profit (USD Million), 2016-2020
Figure 222: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 223: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 224: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
Figure 225: AbbVie Inc. Net Income (USD Million), 2016-2020
Figure 226: AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020
Figure 227: AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020
Global Histone Deacetylase (HDAC) Inhibitors Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 87
The global Histone Deacetylase (HDAC) Inhibitors market was valued at US$ 615.2 million in 2023 and is anticipated to reach US$ 1223.2 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030.
North American market for Histone Deacetylase (HDAC) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Histone Deacetylase (HDAC) Inhibitor......
Global Esomeprazole Magnesium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 74
The global Esomeprazole Magnesium market was valued at US$ 5287 million in 2023 and is anticipated to reach US$ 9451.5 million by 2030, witnessing a CAGR of 8.3% during The forecast period 2024-2030.
North American market for Esomeprazole Magnesium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Esomeprazole Magnesium is estimated to increase from $ million in 2......
Global Combination Therapy Drug Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 86
The global Combination Therapy Drug market was valued at US$ 105 million in 2023 and is anticipated to reach US$ 166.7 million by 2030, witnessing a CAGR of 4.1% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is......
Global Axitinib Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 68
The global Axitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The......
Global Lyme Disease Vaccine Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 70
The lyme disease vaccine can reduce lyme disease incidence, reduce symptoms and reduce mortality. Lyme disease is a tick-borne infection of spirochete, a natural disease caused by borrelia burgdorferi.
The global Lyme Disease Vaccine market was valued at US$ 257 million in 2023 and is anticipated to reach US$ 763 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at......
Global Transdermal Absorption Patch Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Transdermal Absorption Patch market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Transdermal Absorption Patch is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Transdermal Absorption Patch is estimated to increase from $ million i......
Global Ketoprofen Patches Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 78
Ketoprofen patch, indications for The treatment of symptoms caused by The following diseases: rheumatoid arthritis and rheumatoid arthritis
The global Ketoprofen Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Ketoprofen Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast per......
Global Methyl Salicylate Patches Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 82
The global Methyl Salicylate Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to......
Global Diclofenac Patches Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 94
The global Diclofenac Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
